ICON Wins Multiple Categories in 2019 CRO Leadership Awards
05 Março 2019 - 7:00AM
Business Wire
ICON recognised for specialised services
offering across product development lifecycle
ICON plc, (NASDAQ: ICLR) a global provider of drug
development and commercialisation services to the pharmaceutical,
biotechnology and medical device industries, has won awards across
several categories in the annual CRO Leadership Awards.
ICON received 2019 CRO Leadership Awards in five categories,
each further divided into three groups – Big Pharma, Small Pharma,
and Overall. In three categories, ICON took awards in all three
groups.
Winning categories:
- Compatibility (Overall, Big Pharma,
Small Pharma)
- Expertise (Small Pharma)
- Phase IV (Overall, Big Pharma, Small
Pharma)
- Quality (Overall, Big Pharma, Small
Pharma)
- Reliability (Overall, Big Pharma)
This builds on ICON’s success in 2018 when the company won a CRO
Phase IV Leadership Award (Overall, Big Pharma).
For the 2019 CRO Leadership Awards, Life Science Leader magazine
again teamed up with Industry Standard Research (ISR) to determine
the award recipients. Sixty contract research organisations were
assessed on more than 20 performance metrics in ISR’s annual CRO
Quality Benchmarking survey.
Survey participants were recruited from pharma and biopharma
companies of all sizes and were screened for decision-making
influence related to working with contract research
organisations.
“These awards are a testament to the expertise of ICON’s
operational and scientific professionals, and demonstrate the
ownership and outcomes focus we bring to all phases of the drug
development process. It is especially pleasing to see us recognised
both by big and small biopharma companies alike, commented Dr Steve
Cutler, Chief Executive Officer, ICON plc.
“These awards recognise ICON’s comprehensive services, spanning
the entire product development lifecycle and providing seamless
solutions that ultimately lead to better outcomes for our
customers”.
“Life Science Leader is proud to once again be working with ISR
Reports to honor those CROs that have proven themselves to be the
top performers in Compatibility, Capabilities, Expertise, Quality,
Reliability, and Phase IV,” commented Ed Miseta, Executive Editor,
Life Science Leader.
“The winners are selected by their pharma clients, who rate
their CROs on 20+ different performance metrics. We believe the
CROs receiving an award this year are truly at the top of their
class and are deserving of this recognition. Being a top performer
in any of these categories shows a level of expertise and
commitment to clinical trials and serving the needs of
biopharmaceutical companies and their patients.”
“Industry Standard Research continues to consider it an honor to
provide the primary market research data for Life Science Leader’s
CRO Leadership Awards. ISR’s stringent screening processes ensures
that only highly qualified industry decision makers participate in
our CRO benchmarking market research,” commented Andrew Schafer,
President of Industry Standard Research.
“This is paramount as we ask the research participants to
provide experiential, not perceptual, feedback on their involvement
with contract suppliers over the past 18 months. The data enables
users of ISR’s market research to make confident business decisions
based on the experiences of their industry peers.”
ICON previously received CRO Leadership Awards in 2018 and
2015.
A full list of ICON’s industry awards can be viewed
at www.iconplc.com/awards.
About ICON plc
ICON plc is a global provider of outsourced drug development and
commercialisation solutions and services to the pharmaceutical,
biotechnology, medical device and government and public health
organisations. The company specialises in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 90 locations in 37 countries and has
approximately 13,680 employees.
Further information is available at www.iconplc.com
ICON/ICLR-G
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190305005067/en/
ICON Media ContactLucinda Sandon-AllumWeber Shandwick+44
(0)20 7067 0548lsandon-allum@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024